UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv192-iv237

2018

Volltextzugriff (PDF)

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Annals of oncology, 2015-10, Vol.26 (10), p.2073-2078

2015

Volltextzugriff (PDF)

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

European journal of cancer (1990), 2018-01, Vol.88, p.38-47

2018

Volltextzugriff (PDF)

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2023-04, Vol.34 (4), p.339-357

2023

Volltextzugriff (PDF)

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

ESMO open, 2021-10, Vol.6 (5), p.100260-100260, Article 100260

2021

Volltextzugriff (PDF)

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2023-04, Vol.34 (4), p.358-376

2023

Volltextzugriff (PDF)

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2019-05, Vol.30 (5), p.863-870

2019

Volltextzugriff (PDF)

Cancer bronchique non à petites cellules avec anomalies moléculaires actionnables (KRAS, BRAF, MET, fusions)

Revue des maladies respiratoires actualités, 2021-09, Vol.13 (2), p.2S155-2S163

2021

Volltextzugriff (PDF)

Small cell lung cancer: a slightly less orphan disease after immunotherapy

Annals of oncology, 2021-06, Vol.32 (6), p.698-709

2021

Volltextzugriff (PDF)

Spécificités de la prise en charge nutritionnelle en oncologie thoracique

Revue des maladies respiratoires, 2013-06, Vol.30 (6), p.490-497

2013

Volltextzugriff (PDF)

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Annals of oncology, 2020-06, Vol.31 (6), p.798-806

2020

Volltextzugriff (PDF)

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171-210

2019

Volltextzugriff (PDF)

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Annals of oncology, 2020-05, Vol.31 (5), p.609-618

2020

Volltextzugriff (PDF)

Detection of circulating tumour cells with a hybrid (epithelial mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

British journal of cancer, 2011-10, Vol.105 (9), p.1338-1341

2011

Volltextzugriff (PDF)

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Annals of oncology, 2017-07, Vol.28 (7), p.1523-1531

2017

Volltextzugriff (PDF)

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

Annals of oncology, 2017-04, Vol.28 (4), p.784-790

2017

Volltextzugriff (PDF)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2015-05, Vol.26 (5), p.894-901

2015

Volltextzugriff (PDF)

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Annals of oncology, 2022-05, Vol.33 (5), p.466-487

2022

Volltextzugriff (PDF)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

British journal of cancer, 2011-09, Vol.105 (6), p.847-853

2011

Volltextzugriff (PDF)

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Annals of oncology, 2021-11, Vol.32 (11), p.1381-1390

2021

Volltextzugriff (PDF)

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma

Endocrine-related cancer, 2015-06, Vol.22 (3), p.289-298

2015

Volltextzugriff (PDF)

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2016-04, Vol.10 (4), p.395-401

2016

Volltextzugriff (PDF)

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1408-1415

2015

Volltextzugriff (PDF)

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Annals of oncology, 2022-10, Vol.33 (10), p.1041-1051

2022

Volltextzugriff (PDF)

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Annals of oncology, 2019-02, Vol.30 (2), p.161-165

2019

Volltextzugriff (PDF)

1 – 25 von 484

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(455)
Mit Volltextzugriff
(433)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(72)
Humans
(55)
Oncology
(55)
Female
(27)
Male
(27)
Middle Aged
(27)
Aged
(25)
Lung Cancer
(24)
Life Sciences
(20)
Lung Neoplasms - Pathology
(20)
Adult
(17)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(17)
Lung Neoplasms - Drug Therapy
(17)
Respiratory System
(17)
Hematology, Oncology And Palliative Medicine
(16)
Aged, 80 And Over
(15)
Lung Neoplasms - Genetics
(15)
Sciences Biologiques Et Medicales
(15)
Sciences Medicales
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer bronchique non à petites cellules avec anomalies moléculaires actionnables (KRAS, BRAF, MET, fusions)

Small cell lung cancer: a slightly less orphan disease after immunotherapy

Spécificités de la prise en charge nutritionnelle en oncologie thoracique

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Detection of circulating tumour cells with a hybrid (epithelial mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Suchergebnisse filtern